Drug Information

Drug General Information
Drug ID
D03LQC
Former ID
DIB011808
Drug Name
APD-209
Synonyms
Undisclosed cachexia therapy (oral fixed-dose combination), Acacia
Indication Cachexia [ICD9: 799.4; ICD10:R64] Phase 2 [524508]
Company
Acacia Pharma Ltd
Target and Pathway
Target(s) Beta-2 adrenergic receptor Target Info Agonist [544329]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Adrenergic signaling in cardiomyocytes
Salivary secretion
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta2 adrenergic receptor signaling pathway
Pathway Interaction Database Arf6 trafficking events
Arf6 signaling events
Reactome Adrenoceptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Vitamin D Receptor Pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 524508ClinicalTrials.gov (NCT01977443) Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC). U.S. National Institutes of Health.
Ref 544329Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.